Deep Health AI India Ltd Valuation Shifts Signal Heightened Price Risk

Valuation Metrics Reflect Elevated Price Levels

As of 24 April 2026, Deep Health AI’s P/E ratio stands at 6.12, a figure that might superficially appear low but is considered very expensive within the context of its sector and peer group. This valuation is notably lower than some peers such as Khazanchi Jewell, which trades at a P/E of 21.35, but the company’s extremely low PEG ratio of 0.02 indicates that earnings growth expectations are minimal or non-existent, raising questions about the sustainability of current price levels.

The price-to-book value ratio of 1.42 further underscores the premium investors are paying relative to the company’s net asset value. When compared to sector peers like Renaiss. Global and T B Z, which have P/BV ratios that support their “very attractive” valuation tags, Deep Health AI’s elevated P/BV signals a stretched valuation despite its micro-cap status.

Comparative Peer Analysis Highlights Relative Overvaluation

Within the Gems, Jewellery and Watches industry, Deep Health AI’s valuation stands out as an outlier. While companies such as Renaiss. Global and T B Z are classified as very attractive with P/E ratios of 12.11 and 6.9 respectively, and EV/EBITDA multiples below 10, Deep Health AI’s EV/EBITDA ratio of 9.59 aligns with these peers but is overshadowed by its poor growth prospects and weak financial metrics.

Other peers like Asian Star Co. and PNGS Gargi FJ trade at significantly higher multiples (P/E of 28.01 and 29.45 respectively), but these companies often justify their valuations with stronger growth trajectories and operational efficiencies. Deep Health AI’s valuation, therefore, appears disconnected from its fundamental performance.

Financial Performance and Returns Paint a Challenging Picture

Deep Health AI’s return metrics over various periods reveal a concerning trend. Year-to-date, the stock has declined by 56.8%, vastly underperforming the Sensex’s modest 8.87% drop. Over one year, the stock’s return is down 44.97%, compared to the Sensex’s 3.06% loss, and over three years, the stock has plummeted 71.75% while the Sensex has gained 30.19%. These figures highlight significant underperformance and raise questions about the company’s operational resilience and market positioning.

Despite a recent day change of +2.83%, the stock remains near its 52-week low of ₹2.41, far below its 52-week high of ₹10.29. This volatility and downward trend reflect investor scepticism and the challenges faced by the company in regaining market confidence.

Profitability and Efficiency Metrics Offer Limited Comfort

Deep Health AI’s return on capital employed (ROCE) is 14.32%, and return on equity (ROE) is 11.59%, which are moderate but not compelling figures in the context of its valuation. The dividend yield of 3.94% provides some income cushion, yet it is insufficient to offset concerns about growth and valuation.

The company’s EV to capital employed ratio of 1.48 and EV to sales of 7.57 further indicate that the market is pricing in expectations that may not be supported by current operational performance.

Mojo Score and Rating Upgrade Reflect Market Sentiment

MarketsMOJO assigns Deep Health AI a Mojo Score of 22.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 12 December 2025. This downgrade in sentiment aligns with the company’s deteriorating valuation grade, which shifted from expensive to very expensive, signalling increased risk for investors.

The micro-cap classification further emphasises the stock’s vulnerability to market fluctuations and liquidity constraints, making it a less attractive option for risk-averse investors.

Price Movement and Market Capitalisation Context

Trading at ₹2.54 as of the latest session, the stock has seen a slight increase from the previous close of ₹2.47, with intraday highs reaching ₹2.58 and lows at ₹2.41. However, this modest price movement belies the broader downward trend over the past year and beyond.

The company’s market capitalisation remains in the micro-cap range, limiting its visibility and appeal among institutional investors who often prefer larger, more liquid stocks.

Investment Implications and Outlook

Investors analysing Deep Health AI India Ltd should weigh the company’s very expensive valuation against its weak growth prospects and poor relative returns. The low P/E ratio, when viewed in isolation, may seem attractive, but the accompanying very low PEG ratio and deteriorating Mojo Grade suggest that earnings growth is unlikely to support current price levels.

Comparisons with peers reveal that while some companies in the Gems, Jewellery and Watches sector trade at higher multiples, they often justify these valuations with stronger fundamentals and growth outlooks. Deep Health AI’s micro-cap status and recent performance trends indicate elevated risk and limited upside potential.

Given the strong sell recommendation and the shift in valuation grading, investors may consider reducing exposure or seeking alternative investments with more favourable risk-reward profiles within the sector.

Historical Performance Versus Sensex Benchmark

Deep Health AI’s long-term performance starkly contrasts with the broader market. Over the past decade, the stock has delivered a 90.66% return, significantly lagging the Sensex’s 200.58% gain. The three-year return of -71.75% versus the Sensex’s 30.19% gain further highlights the company’s struggles to keep pace with market growth.

Shorter-term returns also paint a bleak picture, with a year-to-date decline of 56.8% compared to the Sensex’s 8.87% drop, underscoring the stock’s heightened volatility and underperformance.

Conclusion: Valuation Reassessment Calls for Caution

Deep Health AI India Ltd’s transition to a very expensive valuation grade, combined with its weak financial metrics and poor relative returns, signals a need for investors to reassess their holdings. The company’s micro-cap status and strong sell Mojo Grade reinforce the risks associated with this stock.

While the recent slight price appreciation may offer short-term relief, the broader fundamental picture suggests that Deep Health AI remains a high-risk proposition within the Gems, Jewellery and Watches sector. Investors are advised to consider more robust alternatives that demonstrate stronger fundamentals and more attractive valuations.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →